Deciphera Pharmaceuticals

Patent cliffs & loss of exclusivity

Deciphera Pharmaceuticals is a biotechnology company founded in 2003 by Daniel Flynn. It develops medicines for cancer and other serious diseases, with research programs in oncology, neurology, immunology and inflammation. Its marketed medicines include QINLOCK and ROMVIMZA. Headquartered in Waltham, Massachusetts, it became a subsidiary of Ono Pharmaceutical in 2024.

Company

Legal NameDeciphera Pharmaceuticals, Inc.
Company Operating StatusAcquired
Crunchbase URLhttps://www.crunchbase.com/organization/deciphera-pharmaceuticals
Email format{f}{last}
Fax Number785.830.2150
Full Address29-31 Rue de Courcelles 75008 Paris, France
LinkedIn URLhttps://www.linkedin.com/company/deciphera-pharmaceuticals/
Pitchbook URLhttps://pitchbook.com/profiles/company/64797-94

4 upcoming patent cliffs

DrugIngredientTypeCliff
  1. QINLOCKRIPRETINIBSmall mol.Oct 2042
  2. ROMVIMZAVIMSELTINIBSmall mol.Apr 2045
  3. ROMVIMZAVIMSELTINIBSmall mol.Apr 2045
  4. ROMVIMZAVIMSELTINIBSmall mol.Apr 2045

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.